Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

11.0K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
11.0K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

2.7K
2.7K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

8.6K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

1.9K
1.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of Label-Free Detection Using Tapered Optical Fiber System for Head and Neck Cancer and Infectious Biomolecules.

Head & neck·2026
Same author

ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.

Cancer research·2026
Same author

Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer.

The Journal of clinical investigation·2026
Same author

NET Rounding: A Standardized Rounding Intervention to Improve Rounding Efficiency and Optimize the Inpatient Experience for Internal Medicine Attendings and Residents.

Southern medical journal·2026
Same author

Targeting STAT3 Promotes Tumor Cell Death and Enhances T-Cell Activity in HPV16-Positive Cancer.

Cancers·2026
Same author

Innovating to Improve Individualized Training in Internal Medicine Residency: Inpatient Threads and Block 2.0.

Journal of general internal medicine·2025

Related Experiment Video

Updated: Apr 20, 2026

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

114.6K

SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.

Qiao-Yang Sun1, Ling-Wen Ding, Jin-Fen Xiao

  • 1Cancer Science Institute of Singapore, National University of Singapore, Singapore.

The Journal of Pathology
|November 19, 2014
PubMed
Summary

SETDB1 protein promotes non-small cell lung cancer (NSCLC) growth by activating the WNT-β-catenin pathway and reducing P53. Targeting SETDB1 may offer a new therapeutic strategy for NSCLC patients.

Keywords:
SETDB1WNTlungtumourigenesis

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector
05:06

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector

Published on: February 2, 2021

2.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

114.6K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector
05:06

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector

Published on: February 2, 2021

2.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • SETDB1 is frequently overexpressed in non-small cell lung cancer (NSCLC).
  • SETDB1's role in NSCLC oncogenesis requires further elucidation.
  • Understanding SETDB1's molecular mechanisms is crucial for targeted therapy development.

Purpose of the Study:

  • To investigate the oncogenic role of SETDB1 in non-small cell lung cancer.
  • To determine the correlation between SETDB1 expression and NSCLC progression.
  • To explore the molecular pathways regulated by SETDB1 in NSCLC.

Main Methods:

  • Immunohistochemistry was performed on 387 NSCLC and 106 normal bronchial epithelium samples.
  • SETDB1 expression was manipulated (forced expression and shRNA silencing) in NSCLC cell lines.
  • In vitro cell growth assays and in vivo murine xenograft models were utilized.
  • WNT-β-catenin pathway activity and P53 expression levels were assessed.

Main Results:

  • SETDB1 was significantly upregulated in NSCLC (72%) compared to normal tissue (46%) (p <0.0001).
  • Increased SETDB1 expression correlated with higher disease grade.
  • Forced SETDB1 expression enhanced NSCLC cell proliferation and tumor growth, while silencing reduced it.
  • SETDB1 promoted WNT-β-catenin signaling and decreased P53 levels.

Conclusions:

  • SETDB1 acts as an oncogene in NSCLC by promoting proliferation and tumor growth.
  • SETDB1 influences NSCLC progression through the WNT-β-catenin pathway and P53 regulation.
  • Therapeutic targeting of SETDB1 presents a promising strategy for NSCLC patients with high SETDB1 expression.